IL200757A0 - Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators - Google Patents

Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators

Info

Publication number
IL200757A0
IL200757A0 IL200757A IL20075709A IL200757A0 IL 200757 A0 IL200757 A0 IL 200757A0 IL 200757 A IL200757 A IL 200757A IL 20075709 A IL20075709 A IL 20075709A IL 200757 A0 IL200757 A0 IL 200757A0
Authority
IL
Israel
Prior art keywords
thiazolidinediones
substituted phenoxy
related receptor
estrogen related
alpha modulators
Prior art date
Application number
IL200757A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL200757(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL200757A0 publication Critical patent/IL200757A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL200757A 2007-03-07 2009-09-06 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators IL200757A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89345307P 2007-03-07 2007-03-07
PCT/US2008/056004 WO2008109727A1 (en) 2007-03-07 2008-03-06 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators

Publications (1)

Publication Number Publication Date
IL200757A0 true IL200757A0 (en) 2010-05-17

Family

ID=39535719

Family Applications (1)

Application Number Title Priority Date Filing Date
IL200757A IL200757A0 (en) 2007-03-07 2009-09-06 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators

Country Status (21)

Country Link
US (2) US7846953B2 (enExample)
EP (1) EP2129668A1 (enExample)
JP (1) JP2010520306A (enExample)
KR (1) KR20090127410A (enExample)
CN (1) CN101679322A (enExample)
AR (1) AR065655A1 (enExample)
AU (1) AU2008222745A1 (enExample)
BR (1) BRPI0808445A2 (enExample)
CA (1) CA2679944A1 (enExample)
CL (1) CL2008000670A1 (enExample)
CO (1) CO6231008A2 (enExample)
EA (1) EA200970837A1 (enExample)
EC (1) ECSP099614A (enExample)
IL (1) IL200757A0 (enExample)
MX (1) MX2009009517A (enExample)
NI (1) NI200900163A (enExample)
NZ (1) NZ579372A (enExample)
SV (1) SV2009003367A (enExample)
TW (1) TW200902508A (enExample)
UA (1) UA98485C2 (enExample)
WO (1) WO2008109727A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
MX2010002538A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
EP2383263B1 (en) * 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG10201402346UA (en) * 2009-05-19 2014-10-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2011019556A1 (en) * 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND
US8927297B2 (en) * 2009-08-11 2015-01-06 Janssen Pharmaceutica N.V. Methods to measure dissociation rates for ligands that form reversible covalent bonds
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
JP5847085B2 (ja) * 2009-10-09 2016-01-20 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション チアゾリジンジオンエネルギー制限模倣剤
EP2598142B1 (en) * 2010-07-28 2015-12-16 Orchid Chemicals and Pharmaceuticals Ltd Diphenyl ether compounds for use in the treatment of liver disorders
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012140300A1 (es) * 2011-04-11 2012-10-18 Servicio Andaluz De Salud Compuestos y composiciones para el tratamiento de mieloma múltiple
ES2390303B1 (es) * 2011-04-11 2013-09-16 Servicio Andaluz De Salud Compuestos y composiciones para el tratamiento de mieloma múltiple.
USD688465S1 (en) 2011-06-14 2013-08-27 Telebrands Corp. Hair detangler
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2868311C (en) 2012-03-26 2021-06-22 Nippon Chemiphar Co., Ltd. Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3050573B1 (en) 2013-09-25 2019-12-11 Nippon Chemiphar Co., Ltd. Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
JP6891118B2 (ja) 2014-12-23 2021-06-18 インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ 経皮投与のための方法及び製剤
KR20180097530A (ko) 2015-11-02 2018-08-31 예일 유니버시티 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114341135B (zh) * 2019-07-04 2025-03-18 领先制药控股公司 雌激素相关受体α(ERRα)调节剂
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
RS64986B1 (sr) * 2019-10-18 2024-01-31 Lead Pharma Holding Bv Modulatori receptora alfa (err-alfa) povezanog sa estrogenom

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
EP1781271A1 (en) * 2004-07-14 2007-05-09 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
US7977489B2 (en) 2004-10-22 2011-07-12 Exelixis, Inc. Benzylthiazolone inhibitors of estrogen-related receptors (ERR)
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
JP2010520307A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−アルファモジュレーターとしての置換フェノキシｎ−アルキル置換チアゾリジンジオン

Also Published As

Publication number Publication date
KR20090127410A (ko) 2009-12-11
WO2008109727A8 (en) 2009-12-17
AR065655A1 (es) 2009-06-24
NZ579372A (en) 2012-02-24
US8344009B2 (en) 2013-01-01
CN101679322A (zh) 2010-03-24
EP2129668A1 (en) 2009-12-09
NI200900163A (es) 2010-07-22
SV2009003367A (es) 2010-08-10
TW200902508A (en) 2009-01-16
JP2010520306A (ja) 2010-06-10
US20090111855A1 (en) 2009-04-30
CA2679944A1 (en) 2008-09-12
ECSP099614A (es) 2009-10-30
CO6231008A2 (es) 2010-12-20
US7846953B2 (en) 2010-12-07
AU2008222745A1 (en) 2008-09-12
MX2009009517A (es) 2009-09-16
UA98485C2 (ru) 2012-05-25
BRPI0808445A2 (pt) 2014-08-05
WO2008109727A1 (en) 2008-09-12
EA200970837A1 (ru) 2010-04-30
US20110237625A1 (en) 2011-09-29
CL2008000670A1 (es) 2008-11-03

Similar Documents

Publication Publication Date Title
IL200757A0 (en) Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
IL200759A0 (en) Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators
ZA200906953B (en) Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators
IL211821A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
AU2009251815A8 (en) 5-substituted isoindoline compounds
ZA201008761B (en) Binder composition
SI2094658T1 (sl) Spojine tetrahidrociklopenta(b)indola kot modulatorji androgenskega receptorja
IL200858A0 (en) Composition for structural adhesive
IL211822A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
PL2102298T3 (pl) Kompozycja dla kleju strukturalnego
GB2443026B (en) Paint binder composition
HK1151982A (en) Novel estrogen receptor ligands
AU2007903545A0 (en) Fertiliser application
AU2007905299A0 (en) Loose material scraper
AU2007903219A0 (en) Chemically Modified Antigenic Composition
AU2008905737A0 (en) Powder Binding Composition
AU2008903493A0 (en) Fertiliser application
AU2008902591A0 (en) A spreading apparatus
HK1136590A (en) Anti-mdl-1 antibodies
HK1153462A (en) Novel compounds as cannabinoid receptor ligands
HK1142905A (en) Novel compounds as cannabinoid receptor ligands
HK1141276A (en) Novel compounds as cannabinoid receptor ligands
HK1140208A (en) Novel compounds as cannabinoid receptor ligands
AU2008905521A0 (en) Fertiliser composition
HK1163084A (en) Thiazoles as cannabinoid receptor ligands